Results from an efficacy study of ReVivo Medical's spinal fusion technology demonstrated that loadsharing through elastic micro-motion accelerates bone formation and interbody fusion.
Bioventus entered into a definitive agreement to divest its next-gen bone morphogenetic protein development program to Viscogliosi Brothers. The transaction is slated to close in 3Q18.
Revo Health and Medtronic entered into a strategic partnership to deliver patient-payment models and enhance outcomes. Medtronic has also made a minority investment in Revo.
Of the 10 companies that announced funding in the first half of the year, just four focus on traditional hardware. Others include biologics, artificial ligaments and software to support device customization.
Vallum received FDA 510(k) clearance to market a PEEK interbody fusion device with a PEEKplus® nanotextured surface created with proprietary Accelerated Neutral Atom Beam technology.